Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY26 results Revenue from operations at Rs 2,363 crore, up 20.4% YoY. EBITDA margins at 19.5% with EBITDA at Rs 460 crore up 27.2% YoY. PAT at Rs 231 crore, up 48.2% YoY. PAT includes Exceptional expense of Rs 38 crore related to labour code changes. Domestic business sales at Rs 1,025 crore, up 15.4% YoY. International business sales at Rs 1,338 crore, up 24.5% YoY. Satish Mehta, CEO & Managing Director, Emcure Pharmaceuticals, said: “Q3 delivered a strong performance, with all our businesses outpacing industry growth. During the period, we strengthened our India portfolio with launch of Poviztra®, a biological injectable semaglutide. Our international business continues to see strong growth led by launch of our differentiated product pipeline. Emcure’s focus remains on improving profitability even as we invest in people, products and processes to drive strong growth. We continue to augment our portfolio in all our focus markets though in-house R&D; and in-licensing. The Novo Nordisk partnership has given Emcure an early-entry advantage, positioning us well in the fast-growing obesity segment. We remain focused on delivering strong growth along with margin improvement.” Result PDF